Bing Xia, MD
Results of the phase III KEYNOTE-189 and IMpower150 trials showed a profound survival benefit in patients with advanced nonsquamous non–small cell lung cancer (NSCLC), when pembrolizumab (Keytruda) and atezolizumab (Tecentriq), respectively, were added to standard chemotherapeutic backbones. Now, selection between the 2 regimens must be based on individual risk factors and comorbidities, explained Bing Xia, MD.
In KEYNOTE-189, patients who received the combination of pembrolizumab, pemetrexed, and platinum-based chemotherapy experienced a 51% reduction in the risk of death compared with those who received chemotherapy alone.1
In IMpower150, the regimen of atezolizumab, carboplatin, paclitaxel, and bevacizumab (Avastin) led to a 22% reduction in the risk of death versus those who received chemotherapy and bevacizumab alone.2
“Now we know that patients do better when we combine chemotherapy and immunotherapy,” said Xia. “If you have a healthy patient with no contraindications to immunotherapy, try the combination upfront.”
... to read the full story